Phosphodiesterase 4 Inhibitor
Positive topline data reported in phase 3 trial of nerandomilast in progressive PF
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-ILD topline results.
Positive topline data reported in phase 3 trial of nerandomilast in adults with IPF
Adults with idiopathic pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast, an investigational phosphodiesterase 4B inhibitor, vs. placebo, according to FIBRONEER-IPF topline results.
Oral Systemic Therapy
Pathogenesis
Pfizer’s phosphodiesterase 4 inhibitor efficacious in atopic dermatitis, psoriasis
MILAN — A basket study of a new topical phosphodiesterase 4 inhibitor demonstrated efficacy superior to that of placebo in mild to moderate plaque psoriasis.
Oral phosphodiesterase 4B inhibitor shows promise for preventing lung function decline in IPF
SAN FRANCISCO — Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use.
VIDEO: Treatment considerations for atopic dermatitis based on disease severity
Amy S. Paller, MD, of Northwestern University Feinberg School of Medicine, discussed how to approach treatment of mild-to-moderate vs. moderate-to-severe atopic dermatitis.